Home > Insider Trading > Filing (0001209191-20-046846)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
879407	Arrowhead Pharmaceuticals Inc.	ARWR	Pharmaceutical Preparations (2834)	460408024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423029	Richard Christopher Anzalone	177 E. Colorado Blvd Suite 700 Pasadena CA 91105	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-13	50,000	$9.90	2,655,237	No	4	M	Direct
Common Stock	Disposition	2020-08-13	50,000	$41.35	2,605,237	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-08-13	50,000	$0.00	50,000	$9.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
895,543	2010-09-01	2020-08-16	No	4	M	Direct

Footnotes

Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the SecuritiesExchange Act of 1934, as amended. This option exercise was completed as the underlying option was due to expire in August 2020.
Includes a total of 1,100,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.
Represents first vesting date. Option vested over four years from date of grant.